(Q34316681)

English

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

ChEBI release 2020-05-28

Isabelle Poizot-Martin

7

object named as

Isabelle Poizot-Martin

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Christine Katlama

4

object named as

Christine Katlama

0 references

Adriano Lazzarin

object named as

Adriano Lazzarin

6

0 references

Bonaventura Clotet Sala

2

object named as

Bonaventura Clotet

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Vicente Soriano

object named as

Vincent Soriano

9

0 references

1

object named as

Joseph J Eron

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Mounir Ait-Khaled

10

object named as

Mounir Ait-Khaled

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Jacques Durant

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Princy Kumar

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Gary Richmond

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Tamio Fujiwara

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Jenny Huang

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sherene Min

13

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Cindy Vavro

14

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Jane Yeo

15

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

VIKING Study Group

16

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

7 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Journal of Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

207

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

740-748

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563307

6 July 2018

Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563307

6 July 2018

Patterns of resistance development with integrase inhibitors in HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563307

6 July 2018

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563307

6 July 2018

Integrase inhibitors in the treatment of HIV-1 infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563307

6 July 2018

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563307

6 July 2018

Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563307

6 July 2018

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563307

6 July 2018

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563307

6 July 2018

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS750

21 January 2018

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS750

21 January 2018

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23225901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/INFDIS/JIS750

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34316681&oldid=1984054055"